Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thermo Fisher ScientificBSP:TMOS34 -0.56%74 EV-to-EBITDA is 19.51 as of Jul. 19, 2026, which is 3% below its 10-year median of 20.13. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$62.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks worse than 61.54% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Thermo Fisher Scientific's enterprise value is R$1,232,861 Mil.
Thermo Fisher Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was R$63,199 Mil. Therefore, Thermo Fisher Scientific's EV-to-EBITDA for today is 19.51.
The historical rank and industry rank for Thermo Fisher Scientific's EV-to-EBITDA or its related term are showing as below:
BSP:TMOS34'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.61 Med: 20.13 Max: 27.47
Current: 20.33
During the past 13 years, the highest EV-to-EBITDA of Thermo Fisher Scientific was 27.47. The lowest was 15.61. And the median was 20.13.
BSP:TMOS34's EV-to-EBITDA is ranked worse than 61.54% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.77
vs BSP:TMOS34: 20.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Thermo Fisher Scientific's PE Ratio (TTM) for today is calculated as:
Thermo Fisher Scientific's share price for today is R$56.89.
Thermo Fisher Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$2.047.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:TMOS34 vs DHR, IDXX, A: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's EV-to-EBITDA falls into.
Thermo Fisher Scientific's current Enterprise Value is R$1,232,861 Mil.
Thermo Fisher Scientific's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$63,199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a EV-to-EBITDA of 19.51 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Thermo Fisher Scientific. This is near median its historical median of 20.13. Over the past decade, Thermo Fisher Scientific's EV-to-EBITDA has ranged from 15.61 to 27.47. According to the industry distribution chart, Thermo Fisher Scientific ranks #72 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 61.5%.
Is Thermo Fisher Scientific's EV-to-EBITDA too high?
Thermo Fisher Scientific's current EV-to-EBITDA of 19.51 is near median its 10-year median of 20.13. Over the past 10 years, this metric has ranged from a low of 15.61 to a high of 27.47. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.77. Thermo Fisher Scientific's value of 19.51 is 32.1% above this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #72 out of 117 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's EV-to-EBITDA compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #72 out of 117 companies for EV-to-EBITDA. This places Thermo Fisher Scientific in the lower half of its industry. The industry median EV-to-EBITDA is 14.77. Thermo Fisher Scientific's value of 19.51 is 32.1% above this benchmark. Historically, Thermo Fisher Scientific's own EV-to-EBITDA has ranged from 15.61 to 27.47 over the past decade. While the company's 10-year median is 20.13 vs. the industry median of 14.77, Thermo Fisher Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.77, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current EV-to-EBITDA of 19.51 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Thermo Fisher Scientific. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current EV-to-EBITDA is 19.51, which is near median its own 10-year median of 20.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$62.63, compared to a current price of R$56.89 — trading 9.2% below its estimated fair value. The current EV-to-EBITDA is 19.51, which is near median its 10-year median of 20.13 and 32.1% above the Medical Diagnostics & Research industry median of 14.77. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current EV-to-EBITDA is 19.51 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$56.89 is trading 9.2% below its estimated GF Value™ of R$62.63.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
EV-to-EBITDA: 19.51 (near median its 10-year median of 20.13)
GF Value™: R$62.63 vs. price of R$56.89 (9.2% below fair value)
Industry Position: 32.1% above the Medical Diagnostics & Research median (#72 of 117)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
